Clinical Trials Logo

Refractory Malignant Glioma clinical trials

View clinical trials related to Refractory Malignant Glioma.

Filter by:

NCT ID: NCT03210714 Active, not recruiting - Clinical trials for Advanced Malignant Solid Neoplasm

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Start date: June 5, 2018
Phase: Phase 2
Study type: Interventional

This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and have come back or do not respond to treatment. Erdafitinib may stop the growth of cancer cells with FGFR mutations by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02208362 Active, not recruiting - Clinical trials for Recurrent Glioblastoma

Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

Start date: May 18, 2015
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of genetically modified T-cell immunotherapy in treating patients with malignant glioma that has come back (recurrent) or has not responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells in the body. T cells are taken from the patient's blood and a modified gene is placed into them in the laboratory and this may help them recognize and kill glioma cells. Genetically modified T-cells may also help the body build an immune response against the tumor cells.